Área salud
Vol. 38. Núm. 7. (Septiembre 2023)
Área salud
Espectro de neuromielitis óptica: ¿seropositivo para la anticuaporina es una entidad diferente de los pacientes que son seronegativos? Una perspectiva de Colombia
Introducción La neuromielitis óptica es una enfermedad inflamatoria del sistema nervioso central, caracterizada por ataques de neuritis óptica y mielitis transversa longitudinalmente extensa. El descubrimiento del biomarcador diagnóstico anticuerpo anti-acuaporina-4 y los hallazgos imagenológicos en […]
Área salud
Microorganismos relacionados con un mayor riesgo de presentar la enfermedad de Parkinson
La enfermedad de Parkinson es un trastorno neurológico degenerativo que afecta a más de 7 millones de personas en todo el mundo. Se desconoce su etiología, aunque se acepta que existe una susceptibilidad genética a […]
Área salud
miR-146a aggravates cognitive impairment and Alzheimer disease-like pathology by triggering oxidative stress through MAPK signaling
Introduction Mir-146a-5p has been widely recognized as a critical regulatory element in the immune response. However, recent studies have shown that miR-146a-5p may also be involved in the development of Alzheimer disease (AD). Regrettably, the […]
Área salud
Auditory cortex hyperconnectivity before rTMS is correlated with tinnitus improvement
Introduction Repetitive transcranial magnetic stimulation (rTMS) has been used as a potential treatment for tinnitus; however, its effectiveness is variable and unpredictable. We hypothesized that resting-state functional connectivity before rTMS may be correlated with rTMS […]
Área salud
Gender may be related to the side of the motor syndrome and cognition in idiopathic Parkinson’s disease
Background and Sex and cognitive profile may be related to the laterality of motor symptoms in idiopathic Parkinson's disease. Introduction Parkinson's disease (PD) is well recognised as an inherently asymmetric disease with unilateral onset of […]
Área salud
Non-late-onset neutropaenia following treatment of multiple sclerosis with ocrelizumab
Late-onset neutropaenia is defined as an absolute neutrophil count of 4 weeks after the last dose of rituximab, in the absence of other identifiable causes. Late-onset neutropaenia is a rare adverse reaction to rituximab (observed […]